• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受辅助化疗的原发性乳腺癌患者的血浆胰岛素样生长因子

Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.

作者信息

Peyrat J P, Révillion F, Bonneterre J

机构信息

Laboratoire d'Oncologie Moléculaire Humaine, Centre Oscar Lambret, Lille, France.

出版信息

Br J Cancer. 1998 May;77(10):1669-71. doi: 10.1038/bjc.1998.274.

DOI:10.1038/bjc.1998.274
PMID:9635846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2150068/
Abstract

Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease in plasma IGF-1.

摘要

对60例接受六个疗程辅助化疗的乳腺癌患者测定了血浆胰岛素样生长因子1（IGF-1）水平。唯一观察到的变化是在化疗的第一疗程和第二疗程之间，治疗前测定的IGF-1浓度略有下降（10%）。在化疗疗程期间，IGF-1没有统计学上的显著变化。这些结果表明，与他莫昔芬和生长抑素等特定激素治疗不同，化疗肯定不是通过降低血浆IGF-1起作用的。

相似文献

1
Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.接受辅助化疗的原发性乳腺癌患者的血浆胰岛素样生长因子
Br J Cancer. 1998 May;77(10):1669-71. doi: 10.1038/bjc.1998.274.
2
Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.原发性乳腺癌辅助化疗期间的血清胰岛素样生长因子-1（IGF-1）和胰岛素样生长因子结合蛋白-3（IGFBP-3）水平。
Breast. 2006 Feb;15(1):64-8. doi: 10.1016/j.breast.2005.04.009. Epub 2005 Jul 5.
3
Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.表柔比星辅助化疗后急性白血病的风险：来自加拿大国家癌症研究所临床试验组的报告
J Clin Oncol. 2003 Aug 15;21(16):3066-71. doi: 10.1200/JCO.2003.08.137.
4
Weight gain during adjuvant and neoadjuvant chemotherapy for breast cancer: an audit of 100 women receiving FEC or CMF chemotherapy.乳腺癌辅助和新辅助化疗期间的体重增加：对100名接受FEC或CMF化疗的女性的审计
Clin Oncol (R Coll Radiol). 2002 Feb;14(1):64-7. doi: 10.1053/clon.2001.0014.
5
Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer pre-menopausal patients.环磷酰胺、甲氨蝶呤和5-氟尿嘧啶辅助化疗对绝经前乳腺癌患者血浆胰岛素样生长因子-I及所选激素的影响
J Clin Pharm Ther. 2000 Feb;25(1):67-72. doi: 10.1046/j.1365-2710.2000.00265.x.
6
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.随机对照试验：三苯氧胺对比三苯氧胺联合兰瑞肽治疗绝经后早期乳腺癌的辅助治疗：NCIC CTG MA.14。
J Clin Oncol. 2011 Oct 10;29(29):3869-76. doi: 10.1200/JCO.2010.33.7006. Epub 2011 Sep 12.
7
Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.粒细胞集落刺激因子（G-CSF）支持的剂量递增氟尿嘧啶/表柔比星/环磷酰胺（FEC）疗法作为乳腺癌术后辅助治疗的急性血液学可行性。
Anticancer Res. 1999 Sep-Oct;19(5C):4429-34.
8
[Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer].[FEC 100序贯DOC 100作为乳腺癌辅助化疗的可行性]
Gan To Kagaku Ryoho. 2010 Aug;37(8):1483-7.
9
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).FEC 方案与序贯多西他赛联合表柔比星/环磷酰胺作为腋窝淋巴结阳性早期乳腺癌辅助化疗方案的比较：希腊肿瘤研究组（HORG）的一项随机研究。
Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28.
10
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.绝经前、淋巴结阳性乳腺癌患者中基于表柔比星的辅助化疗六个周期与三个周期的随机试验：法国辅助研究组01试验的10年随访结果
J Clin Oncol. 2003 Jan 15;21(2):298-305. doi: 10.1200/JCO.2003.04.148.

本文引用的文献

1
Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.胰岛素样生长因子1（IGF-1）通过抑制多种抗癌药物诱导的细胞凋亡来改变HBL100人乳腺癌细胞的药物敏感性。
Cancer Res. 1997 Jul 1;57(13):2687-93.
2
Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.他莫昔芬可干扰乳腺癌细胞中的胰岛素样生长因子I受体（IGF-IR）信号通路。
Cancer Res. 1997 Jul 1;57(13):2606-10.
3
Insulin-like growth factors and breast cancer.胰岛素样生长因子与乳腺癌
Biomed Pharmacother. 1995;49(9):415-21. doi: 10.1016/0753-3322(96)82678-3.
4
Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer.人乳腺癌中的血浆胰岛素样生长因子-1（IGF-1）浓度
Eur J Cancer. 1993;29A(4):492-7. doi: 10.1016/s0959-8049(05)80137-6.
5
Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy.
Eur J Cancer. 1993;29A(10):1368-72. doi: 10.1016/0959-8049(93)90003-x.
6
Nutritional regulation of the insulin-like growth factors.胰岛素样生长因子的营养调节
Endocr Rev. 1994 Feb;15(1):80-101. doi: 10.1210/edrv-15-1-80.
7
Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance.胰岛素样生长因子-1抑制MCF-7细胞中抗癌药物诱导的细胞死亡：生长因子与耐药性的关系。
Cancer Invest. 1995;13(5):480-6. doi: 10.3109/07357909509024911.
8
Pathophysiological and clinical aspects of the insulin-like growth factors.
Horm Res. 1986;24(2-3):160-5. doi: 10.1159/000180555.
9
Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer.
Cancer Res. 1989 Apr 1;49(7):1882-4.
10
Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.
Anticancer Res. 1989 Jul-Aug;9(4):889-91.